Zacks Investment Research Releases Upgraded Equity Research Report on Pressure BioSciences, Inc. (OTCQB: PBIO)
SOUTH EASTON, Mass., Nov. 29, 2012 /PRNewswire/ — Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”) today announced that Zacks Investment Research (“Zacks”) has released an upgraded equity research report on the Company. Zacks is a leading provider of independent equity research.
Copies of this research report can be obtained by contacting:
- Mr. Timothy Connor, Managing Director, Benchmark Advisory Partners, 7817 Herschel Ave, Suite 201, La Jolla, CA 92037, (858) 568-7059, email@example.com, or
- Mr. Grant Zeng, CFA, Zacks Equity Research, 111 North Canal Street, Chicago, IL, 60606, (312-630-9880 x9466), (firstname.lastname@example.org), or by contacting Zacks directly through their website (www.zacks.com).
Any opinions, judgments, estimates, or forecasts regarding the Company’s historical or predicted performance or operations made by Zacks are theirs alone and do not represent opinions, judgments, estimates, or forecasts of the Company or its management. The Company does not by its reference to the research prepared by Zacks imply its endorsement or adoption of or concurrence with such information, conclusions, or recommendations.
Founded in 1978 in Chicago, Zacks Investment Research, Inc. is one of the largest independent investment research and consulting firms in the United States. With over 30 years of experience dedicated to providing clients with the highest standards of services, Zacks has become an industry leader in providing institutional and individual investors with the analytical tools and financial information necessary to the success of their investment process.
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (“PBI”) (OTCQB: PBIO) is focused on the development, marketing, and sale of proprietary laboratory instrumentation and associated consumables based on Pressure Cycling Technology (“PCT”). PCT is a patented, enabling technology platform with multiple applications in the estimated $6 billion life sciences sample preparation market. PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. PBI currently focuses its efforts on the development and sale of PCT-enhanced sample preparation systems (instruments and consumables) for mass spectrometry, biomarker discovery, bio-therapeutics characterization, vaccine development, soil and plant biology, forensics, histology, and counter-bioterror applications.
For more information about PBI and this press release, please click on the following website link:
Investor Contacts: Richard T. Schumacher, President (508) 230-1828 and CEO, PBI (T) Timothy J. Connor, Managing (858) 568-7059 Director, Benchmark Advisory (T)
SOURCE Pressure BioSciences, Inc.